Mankind Pharma
2,476.60
+21.30(+0.87%)
Market Cap₹1,01,344.60 Cr
PE Ratio53.48
IndustryHealthcare
Company Performance:
1D+0.87%
1M-3.64%
6M-4.07%
1Y-7.72%
5Y+74.13%
View Company Insightsright
More news about Mankind Pharma
21Aug 25
Mankind Pharma Sees Rs. 50.95 Crore Block Trade on NSE
A significant block trade of Mankind Pharma Ltd. shares occurred on the National Stock Exchange (NSE). The transaction involved 202,622 shares at Rs. 2,514.70 per share, totaling Rs. 50.95 crore. This large-scale trade, likely involving institutional investors, highlights ongoing interest in the pharmaceutical sector and Mankind Pharma's market position. The company is known for its diverse portfolio of affordable medicines and strong presence in various therapeutic segments.
09Aug 25
Mankind Pharma Confident in Anti-Diabetic Portfolio Despite GLP-1 Therapy Rise; Reports Strong Q1 Growth
Mankind Pharma's CEO Sheetal Arora expressed confidence in the company's anti-diabetic drug portfolio, citing strong performance in chronic therapies. The company reported 24.5% revenue growth to 3570.00 and 26.1% EBITDA growth to 847.00. An interim dividend of Re 1 per share was approved. At the 34th AGM, shareholders approved financial statements, re-appointed Sheetal Arora as director, and appointed new Secretarial Auditors for a five-year term.
03Aug 25
Mankind Pharma Seeks Reclassification of Ayushi and Poonam Estates LLP to Public Category
Mankind Pharma Limited has applied to BSE and NSE to reclassify Ayushi and Poonam Estates LLP from 'Promoter & Promoter Group' to 'Public' category. The application, made on August 3, 2025, follows a board meeting on July 31, 2025. The request complies with SEBI's LODR Regulations, 2015. The reclassification, if approved, could impact Mankind Pharma's shareholding structure and corporate governance.
02Aug 25
Mankind Pharma Reaffirms FY26 Margin Goals, Eyes Global Dydrogesterone Approvals
Mankind Pharma has confirmed its FY26 financial targets, aiming for an EBITDA margin of 25-26% and a gross margin above 70%. The company expects global approvals for dydrogesterone by end of 2025, supporting its international growth strategy. Mankind Pharma recently held an investor conference call for Q1 FY26 on August 1, 2025, demonstrating commitment to shareholder communication.
31Jul 25
Mankind Pharma Reports 24.5% Revenue Growth in Q1, Profit Declines
Mankind Pharma announced Q1 financial results with consolidated revenue of ₹3,570.00 crore, up 24.5% year-over-year. Domestic revenue grew 18.9% to ₹3,101.00 crore, while exports surged 81.1% to ₹469.00 crore. Despite revenue growth, net profit declined 17.4% to ₹445.00 crore. EBITDA margin stood at 23.8%. The company maintained its #1 rank in prescriptions and increased its market share to 4.9%. An interim dividend of ₹1.00 per share was approved.
30Jul 25
Mankind Pharma Expected to Report Revenue Growth but Lower Net Profit in Q1 Results
Mankind Pharma is expected to report a significant revenue increase to Rs 3,605.53 crore in Q1, up from Rs 2,893.42 crore last year, largely due to the Bharat Serum Vaccine (BSV) acquisition. BSV is projected to contribute Rs 470.00 crore to the top line. However, net profit may decline to Rs 446.71 crore from Rs 536.49 crore. EBITDA is estimated to improve to Rs 900.11 crore with a margin expansion to 25.00%. Analysts maintain a positive outlook, with IIFL Capital giving a 'Buy' rating and Axis Capital projecting 24% year-on-year growth in consolidated sales.
24Jul 25
Mankind Pharma Expands into Sri Lanka with New Wholly Owned Subsidiary
Mankind Pharma has incorporated a fully owned subsidiary named Mankind Pharma Lanka (Private) Limited in Sri Lanka on July 23, 2025. This strategic move marks the company's direct entry into the Sri Lankan pharmaceutical market, potentially enhancing its presence in South Asia. The expansion could allow Mankind Pharma to gain direct access to Sri Lankan consumers, tailor products to local needs, and improve regional distribution capabilities.
24Jul 25
Mankind Pharma Incorporates Wholly Owned Subsidiary in Sri Lanka
Mankind Pharma has incorporated a wholly owned subsidiary, Mankind Pharma Lanka (Private) Limited, in Sri Lanka on July 23. The company officially notified the BSE and NSE about this development on July 24, in line with its previous disclosure on May 21. This move is part of Mankind Pharma's strategy to expand its international operations and strengthen its presence in the South Asian market.
22Jul 25
Mankind Pharma Receives Request for Promoter Group Reclassification
Ayushi and Poonam Estates LLP has requested reclassification from 'Promoter and Promoter Group' to 'Public' category in Mankind Pharma. The LLP's ownership has been transferred to Chalet Hotels Limited and Sonmil Industries Private Limited, with new designated partners. The LLP holds no shares in Mankind Pharma and claims no control over company affairs. The request will be considered by Mankind Pharma's board in an upcoming meeting, subject to SEBI regulations.
22Jul 25
Mankind Pharma Receives Request for Reclassification of Promoter Group Entity
Ayushi and Poonam Estates LLP, currently classified under Mankind Pharma's 'Promoter and Promoter Group', has requested reclassification to the 'Public' category following a complete ownership transfer. The LLP, now owned by Chalet Hotels Limited and Sonmil Industries Private Limited, cites no shareholding in Mankind Pharma, lack of control over company affairs, and absence of special rights or board representation as reasons for the request. The reclassification aligns with SEBI regulations and will be considered by Mankind Pharma's board in an upcoming meeting.
02Jun 25
Mankind Pharma Launches 'Kindcare Foundation' as Non-Profit Subsidiary
Mankind Pharma has established a new wholly owned subsidiary named 'Kindcare Foundation', a not-for-profit organization aimed at enhancing its corporate social responsibility efforts. This move signifies the company's increased commitment to social welfare and community development. While specific activities are not yet disclosed, the foundation is expected to focus on areas such as healthcare accessibility, disease awareness, and community health initiatives. This development is likely to be viewed positively by investors, employees, communities, and regulators.
22May 25
Mankind Pharma Reports Mixed Q4 Results, Dolat Capital Adjusts Target Price
Mankind Pharma's Q4 results show an 18.40% year-on-year growth in domestic formulation revenues, driven by BSV consolidation and strong performance in chronic therapies. Excluding BSV, growth was 10.00%. Dolat Capital maintains 'Add' rating but revises target price downward.
21May 25
Mankind Pharma Q4 Results: Revenue Surges 27%, Profit Dips 10.7% YoY
Mankind Pharma's Q4 results show strong revenue growth of 27.10% YoY to ₹3,079.40 crore, driven by chronic therapies and consumer healthcare segments. However, net profit declined by 10.70% to ₹420.80 crore. EBITDA increased by 16.50% to ₹688.50 crore, but margins faced pressure. Full-year revenue grew 19% to ₹12,207.00 crore. The company's performance reflects robust market presence amid competitive challenges in the pharmaceutical industry.
20May 25
Mankind Pharma Q4 Results: Revenue Growth Expected Amid Profit Concerns
Mankind Pharma is set to release its Q4 results with analysts projecting a 26.8% YoY revenue growth to Rs 3,095.70 crore. However, net profit is expected to decline by 22.3%. The company faces margin pressure, with EBITDA margin projected to decrease from 28% to 25.6% YoY. Key focus areas include domestic business growth, Bharat Serum Vaccine contribution, and tariff-related risks. Recent financial data shows revenue up 23.46% YoY but net profit down 16.38% YoY in the previous quarter.
14May 25
Mankind Pharma Faces Rs 341.86 Crore Tax Demand, Plans to Appeal
Mankind Pharma Ltd has received additional tax demands of Rs 341.86 crore from the Income Tax authority. The company intends to challenge these orders, believing them to be 'untenable in law'. Despite the significant amount, Mankind Pharma does not anticipate any material impact on its financials or operations. The company's confident response suggests it is prepared to handle the situation, with the outcome potentially having implications for the pharmaceutical sector.
08May 25
Mankind Pharma Sets Date for Q4 Financial Results Review
Mankind Pharma has scheduled a review of its fourth quarter financial results for May 21, 2023. This announcement signals the company's readiness to disclose its earnings report for the final quarter of the fiscal year. The review will provide insights into the company's financial performance, including revenue figures, profit margins, sales growth, and market share updates.
15Apr 25
Mankind Pharma Unveils Strategic Expansion with New Subsidiaries and Integration Plans
Mankind Pharma has approved several strategic initiatives: establishing a wholly-owned subsidiary in Russia with a $5 million investment to distribute BSV products, creating an Indian subsidiary for CSR activities with Rs. 5 lakh initial investment, and forming a committee to explore integration options for Bharat Serums and Vaccines Limited. These actions aim to expand the company's global footprint and streamline operations, subject to regulatory approvals.
14Apr 25
Mankind Pharma Unveils Major Corporate Restructuring and Global Expansion Strategy
Mankind Pharma has revealed strategic initiatives including potential integration of Bharat Serums and Vaccines, establishment of a Russian subsidiary with $5 million investment for product distribution, and creation of an Indian CSR subsidiary. The company's board approved these plans on April 14, 2025, signaling a new growth phase. The Russian subsidiary will distribute BSV products, while the Indian entity will manage CSR activities with an initial Rs. 5 lakh investment. These moves are subject to various regulatory approvals.
01Apr 25
Mankind Pharma Faces ₹183 Crore Tax Demand Amidst Strong Financial Growth
Mankind Pharma faces an additional tax demand of ₹183 crore ($22 million) from Indian tax authorities. Despite this, the company's financial position remains robust, with significant year-over-year growth in key metrics. Total assets increased by 21.84% to ₹11,417.70 crore, current assets rose by 56.11% to ₹5,490.40 crore, and total equity grew by 23.64% to ₹9,623.80 crore in FY 2024. The tax demand represents 1.60% of the company's total assets, suggesting Mankind Pharma is well-positioned to manage this liability.
01Apr 25
Mankind Pharma Announces NCLT Approval for BSV Pharma-Bharat Serums Merger
Mankind Pharma announced that the National Company Law Tribunal (NCLT) has approved the amalgamation of BSV Pharma with Bharat Serums and Vaccines. This merger in the Indian pharmaceutical industry is expected to combine the strengths and resources of both entities, potentially leading to enhanced operational efficiencies, expanded product portfolios, and strengthened market presence.
29Mar 25
Mankind Pharma Completes Merger of Three Subsidiaries, Adjusts Authorized Share Capital
Mankind Pharma has finalized the amalgamation of three subsidiaries - Shree Jee Laboratory, JPR Labs, and Jaspack Industries - effective March 29, 2025. The merger, approved by NCLT New Delhi, transfers all assets and liabilities to Mankind Pharma. The company's authorized share capital has been revised to ₹421.51 crore. Additionally, NCLT Mumbai has approved the merger of BSV Pharma with Bharat Serums and Vaccines Limited, a material subsidiary of Mankind Pharma.
28Mar 25
Mankind Pharma's Subsidiary Merger Approved by NCLT; Company Faces Tax Assessment Orders
Mankind Pharma's subsidiary Bharat Serums and Vaccines Limited (BSVL) received NCLT approval to merge with BSV Pharma Private Limited, effective May 9, 2022. The merger aims to consolidate operations and improve efficiency. Separately, Mankind Pharma received income tax assessment orders for 2014-15 to 2017-18, with additional tax demands of ₹183.11 crore. The company plans to appeal, asserting the demands are not legally tenable.
21Mar 25
Mankind Pharma Set to Benefit from FTSE All World Index Upgrade
Mankind Pharma has been upgraded in the FTSE All World Index, expected to bring in $16 million (₹133 crore) of foreign investment. This upgrade is likely to increase the company's global visibility and potentially improve stock liquidity. Index funds and ETFs tracking the FTSE All World Index may need to adjust their holdings, possibly leading to automatic buying of Mankind Pharma stock.
12Mar 25
Mankind Pharma Launches Generic Empagliflozin for Diabetes Treatment in India
Mankind Pharma has introduced generic Empagliflozin under three brand names: Empaglyde, Empagreat, and Dynaduo. The medication is available in 10mg tablets priced at ₹5.49 and 25mg tablets at ₹9.90. This launch follows the expiration of Boehringer Ingelheim's patent in India. The move aims to increase accessibility and affordability of diabetes treatment, potentially capturing a significant market share. It aligns with Mankind Pharma's strategy to expand in the chronic diseases segment, particularly diabetes care.
10Mar 25
Mankind Pharma Set to Revolutionize Diabetes Treatment with Affordable Empagliflozin
Mankind Pharma is set to introduce generic versions of Empagliflozin, a crucial diabetes medication, at prices up to 85% lower than current market rates. The company plans to offer the drug at Rs 9-14 per tablet, compared to the current price of Rs 60. This move is part of a broader trend in the Indian pharmaceutical industry to make diabetes treatments more accessible. The launch is expected to significantly impact the diabetes care market in India, potentially improving treatment outcomes for millions of patients.
03Mar 25
Mankind Pharma Faces ₹112 Crore Tax Demand, Plans to Appeal
Mankind Pharma has received an additional tax demand of ₹112 crore from the Income Tax Department. The company believes the demand is not legally tenable and intends to appeal against the order. Mankind Pharma does not expect any material impact on its financial position or operations due to this development.
28Feb 25
Mankind Pharma Faces ₹111.68 Crore Tax Demand, Plans to Appeal
Mankind Pharma has received an additional tax demand of ₹111.68 crore from the Income Tax Department for the Assessment Year 2021-22. The demand stems from adjustments under sections 80IC/80IE and disallowances under section 37(1) of the Income-tax Act. The company believes the demand is not tenable and plans to appeal, stating it has adequate grounds to support its case. Mankind Pharma does not expect any material impact on its financials or operations due to this order.
28Feb 25
Mankind Pharma's MSCI Weightage Increase and Subsidiary Merger Approval
Mankind Pharma's weightage in the MSCI India Standard Index is set to increase, potentially attracting $48 million inflow. The company has also received NCLT approval to merge three wholly-owned subsidiaries, aiming to streamline operations, optimize resources, and enhance competitive advantage. The merger's appointed date is April 1, 2024, with NCLT approval on February 25, 2025.
27Feb 25
NCLT Greenlights Mankind Pharma's Strategic Consolidation Move
The National Company Law Tribunal (NCLT) has approved the amalgamation of three wholly-owned subsidiaries with Mankind Pharma Limited, effective April 1, 2024. The merger aims to consolidate resources, enhance operational synergies, optimize costs, and improve financial management. This strategic move is expected to strengthen Mankind Pharma's position in the pharmaceutical industry without immediate impact on shareholders. The company's stock showed a marginal increase of 0.04% following the announcement.
Mankind Pharma
2,476.60
+21.30
(+0.87%)
1 Year Returns:-7.72%
Industry Peers
Sun Pharmaceutical
1,679.10
(+1.21%)
Divis Laboratories
6,621.50
(+0.32%)
Cipla
1,577.60
(+0.52%)
Torrent Pharmaceuticals
3,584.30
(+1.43%)
Dr Reddys Laboratories
1,255.90
(+1.27%)
Mankind Pharma
2,476.60
(+0.87%)
Zydus Life Science
987.65
(+0.31%)
Lupin
1,940.00
(-0.57%)
Alkem Laboratories
5,581.50
(+1.04%)
Aurobindo Pharma
1,101.00
(-0.48%)